Analysts Set Vivos Therapeutics, Inc. (NASDAQ:VVOS) PT at $4.92

Vivos Therapeutics, Inc. (NASDAQ:VVOS) has received an average rating of “Hold” from the five ratings firms that are covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating on the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $4.9167.

Several equities analysts have recently issued reports on VVOS shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of Vivos Therapeutics in a report on Wednesday, January 21st. HC Wainwright began coverage on Vivos Therapeutics in a research note on Monday, November 17th. They set a “buy” rating and a $7.00 price objective for the company. Ascendiant Capital Markets dropped their target price on Vivos Therapeutics from $6.50 to $5.50 and set a “buy” rating on the stock in a report on Wednesday, December 3rd. Finally, Zacks Research raised Vivos Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Monday, December 1st.

Institutional Trading of Vivos Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of VVOS. Acorn Wealth Advisors LLC bought a new position in shares of Vivos Therapeutics in the fourth quarter worth approximately $30,000. XTX Topco Ltd bought a new position in Vivos Therapeutics in the 2nd quarter valued at approximately $65,000. B. Riley Wealth Advisors Inc. bought a new position in Vivos Therapeutics in the 2nd quarter valued at approximately $220,000. DRW Securities LLC boosted its stake in Vivos Therapeutics by 179.5% during the 4th quarter. DRW Securities LLC now owns 115,907 shares of the company’s stock valued at $235,000 after purchasing an additional 74,441 shares during the last quarter. Finally, Connective Capital Management LLC bought a new stake in shares of Vivos Therapeutics in the 3rd quarter worth $620,000. 26.35% of the stock is currently owned by institutional investors.

Vivos Therapeutics Trading Down 3.4%

Shares of NASDAQ VVOS opened at $1.40 on Wednesday. Vivos Therapeutics has a 1 year low of $1.37 and a 1 year high of $7.95. The company has a debt-to-equity ratio of 3.31, a current ratio of 0.78 and a quick ratio of 0.78. The firm has a 50-day moving average of $1.84 and a 200 day moving average of $2.65. The stock has a market cap of $14.66 million, a P/E ratio of -0.79 and a beta of 6.93.

About Vivos Therapeutics

Vivos Therapeutics, Inc is a medical technology company focused on the development and commercialization of oral appliance therapy for the treatment of obstructive sleep apnea (OSA) and other airway-related disorders. The company’s proprietary Vivos System integrates clinical diagnostic protocols, three-dimensional imaging, and custom-designed dental appliances to address mild to moderate forms of sleep-disordered breathing through non-surgical, non-invasive means.

The Vivos System comprises a range of custom oral devices, digital workflow tools, and a structured treatment protocol.